@article{81c81334037445cd80c31dbac6236659,
title = "Treatment of myelin oligodendrocyte glycoprotein antibody associated disease with subcutaneous immune globulin",
abstract = "Myelin oligodendrocyte glycoprotein (MOG)-antibody associated disease (MOGAD) is a distinct demyelinating disease of the central nervous system that often exhibits a relapsing course. Immune globulin (Ig) therapy has been proposed as maintenance therapy to prevent relapses in MOGAD, but existing reports are limited to the use of intravenous Ig (IVIG). Subcutaneous Ig (SCIG) may exhibit several advantages over IVIG, including self-administration and less systemic adverse effects. Herein, we report six patients with MOGAD who were treated with subcutaneous Ig (SCIG) with good tolerability and without any relapses during follow-up. This supports the rationale for prospective randomized studies of SCIG in MOGAD.",
author = "Sotirchos, {Elias S.} and Vasileiou, {Eleni S.} and Rebecca Salky and Saif Huda and Sara Mariotto and Chen, {John J.} and Michael Levy",
note = "Funding Information: Elias Sotirchos has received speaker honoraria from Viela Bio and Biogen and has served on scientific advisory boards for Viela Bio, Alexion and Genentech. Eleni Vasileiou, Rebecca Salky and Saif Huda report no disclosures. Sara Mariotto reports speaker honoraria from Biogen and Novartis and has received research funding from Euroimmun. John Chen reports consulting for UCB and Roche. Michael Levy has received personal compensation from Alexion, Horizon, Genentech/Roche, Sanofi, and UCB for work on advisory boards and his lab has received grant funding from Alexion, Horizon, Genentech/Roche and Bluerock. Publisher Copyright: {\textcopyright} 2021",
year = "2022",
month = jan,
doi = "10.1016/j.msard.2021.103462",
language = "English (US)",
volume = "57",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",
}